within Pharmacolibrary.Drugs.ATC.A;

model A07AA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 90 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Kanamycin is an aminoglycoside antibiotic primarily used to treat severe bacterial infections such as tuberculosis caused by Mycobacterium tuberculosis and other susceptible bacteria. It is usually reserved for infections resistant to other antibiotics due to its potential toxicities. Kanamycin is approved but is less commonly used today due to the availability of less toxic alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult individuals receiving kanamycin intramuscularly.</p><h4>References</h4><ol><li><p>Clarke, JT, et al., &amp; Kirby, WM (1974). Comparative pharmacokinetics of amikacin and kanamycin. <i>Clinical pharmacology and therapeutics</i> 15(6) 610–616. DOI:<a href=&quot;https://doi.org/10.1002/cpt1974156610&quot;>10.1002/cpt1974156610</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4210297/&quot;>https://pubmed.ncbi.nlm.nih.gov/4210297</a></p></li><li><p>Chang, MJ, et al., &amp; Park, JS (2017). Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. <i>International journal of antimicrobial agents</i> 49(6) 677–687. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2017.01.024&quot;>10.1016/j.ijantimicag.2017.01.024</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28408267/&quot;>https://pubmed.ncbi.nlm.nih.gov/28408267</a></p></li><li><p>el-Gammal, AA, et al., &amp; Saad, A (1992). Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing. <i>Journal of veterinary pharmacology and therapeutics</i> 15(2) 133–142. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1992.tb01000.x&quot;>10.1111/j.1365-2885.1992.tb01000.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1433475/&quot;>https://pubmed.ncbi.nlm.nih.gov/1433475</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07AA08;
